Breakthrough breast cancer logo
sitemap
  • Breakthrough Research homepage
  •  | 
  • Vacancies
Sign in to Extranet
  • Home
  • About Breakthrough
  • Breakthrough Research Centre
    • History & Funding
    • The Director
    • Research Teams
      • Apoptosis
      • Cancer Informatics
      • Drug Target Discovery
      • Gene Function
      • Mammary Stem Cells
      • Molecular Cell Biology
      • Molecular Endocrinology
        • Projects
        • The Team
        • Team Leader
        • Publications
      • Molecular Pathology
      • Translational Research
    • Scientific Support
    • Contact Us
  • Research Units & Programmes
  • Breakthrough Generations & Population Studies
  • Clinical Trials & Clinical Researchers
  • Research Funding
  • News & events
Projects

Projects

Using in vitro systems modeling relapse on tamoxifen or aromatase inhibitors, our studies focus on alterations in signal transduction pathways and their impact on proliferation, survival, invasion and angiogenesis.

  • Molecular profiling of human breast tumour cells modelling relapse on tamoxifen or after long-term oestrogen deprivation
  • Coactivator/corepressor interactions with ER in the endocrine resistant setting
    Establishing the role of coactivator/corepressors associated with ER in LTED and TamR cells.
  • Role of oestrogen receptor (ER) and HER-2 in the regulation of VEGF and tumour angiogenesis in endocrine resistant breast tumours
    Investigating ER regulation of VEGF in an acquired endocrine resistant model.
  • Transcriptional profiles of endocrine resistant cells
    Establishing how other key pathways controlling cell proliferation are deregulated using microarray.
  • Invasive potential of endocrine resistant cells
    Focused on the invasive phenotype of these resistant cell lines and possible points for therapeutic intervention.
  • Combination of signal transduction inhibitors with endocrine agents
    Investigating ways to improve the efficacy of current endocrine agents as well as delaying the onset of resistance by targeting concomitantly ER and pertinent signal transduction pathways.

See also

  • The Team
  • Team Leader
  • Publications
Back to top
© Breakthrough Breast Cancer 2008 | Privacy | Sitemap
The Institute of Cancer Research